Skip to main contentAI and Advanced
/
AUROPHARMA · NSEMarket ticker unavailable · configure an authorised index feed
AU
NSE · Equity shares · Major Drugs-17.00 · -1.02%
Aurobindo Pharma AUROPHARMA
NSE:INR 1,643
BSE:INR 1,589.5
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for AUROPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,660
Day rangeINR 1,623 — INR 1,657.1
52-week rangeINR 1,036 — INR 1,717
Volume5.23 L
Market cap91,456.32
P/E21.62
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)33,653.08
Net Income (INR Cr)3,504.75
Rev Growth (5 Year %)6.32
EPS Growth (5 Year %)-7.9
P/E Ratio21.62
Book Value561.46
EPS61.98
Price/BV2.93Computed
Research path: Interpret Aurobindo Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AUROPHARMAAurobindo Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 58,502.15 | 49,784.97 | 45,071.51 |
| Accumulated Depreciation Total | -7,904.59 | -6,538.47 | -6,372.69 |
| Cash Equivalents | 5,376.68 | 2,919.57 | 2,110.91 |
| Other Liabilities Total | 1,178.64 | 351.57 | 277.59 |
| Accrued Expenses | 503.71 | 246.26 | 346.26 |
| Long Term Debt | 802.75 | 1,561.65 | 2,134.9 |
| Common Stock Total | 58.08 | 58.08 | 58.59 |
| Other Equity Total | 3,799.05 | 1,838.52 | 1,517.99 |
| Other Current Assets Total | 70.22 | 43.13 | 445.24 |
| Total Assets | 58,502.15 | 49,784.97 | 45,071.51 |
| Current Portof LT Debt/Capital Leases | 897.51 | 1,152.29 | 182.08 |
| Additional Paid-In Capital | 75.11 | 75.11 | 417.89 |
| Cash | 1,814.72 | 2,649.38 | 1,282.57 |
| Total Equity | 37,890.97 | 32,653.32 | 29,842.8 |
| Long Term Investments | 303.88 | 251.7 | 321.65 |
| Retained Earnings(Accumulated Deficit) | 33,958.73 | 30,681.61 | 27,848.33 |
| Total Common Shares Outstanding | 58.08 | 58.08 | 58.59 |
| Property/Plant/Equipment Total-Gross | 25,243.35 | 21,993.9 | 20,657.59 |
| Tangible Book Valueper Share Common Eq | 561.46 | 489.23 | 439.74 |
| Goodwill Net | 800.15 | 618.02 | 595.15 |
| Total Liabilities | 20,611.18 | 17,131.65 | 15,228.71 |
| Total Debt | 8,072.84 | 8,262.87 | 6,647.63 |
| Short Term Investments | 3,393.52 | 2,632.33 | 2,932.88 |
| Cashand Short Term Investments | 10,584.92 | 8,201.28 | 6,326.36 |
| Total Receivables Net | 10,000.67 | 8,374.33 | 7,625.8 |
| Notes Payable/Short Term Debt | 6,079.64 | 5,309.72 | 4,078.12 |
| Deferred Income Tax | 306 | 303.27 | 356.56 |
| Accounts Receivable-Trade Net | 7,120.69 | 5,873.95 | 5,036.43 |
| Property/Plant/Equipment Total-Net | 17,338.76 | 15,455.43 | 14,284.9 |
| Minority Interest | -8.16 | -6.39 | 8 |
| Total Current Liabilities | 18,039.01 | 14,682.34 | 12,199.13 |
| Total Inventory | 12,052.94 | 10,543.72 | 9,808.23 |
| Accounts Payable | 5,567.27 | 4,188.85 | 4,454.16 |
| Other Currentliabilities Total | 4,990.88 | 3,785.22 | 3,138.51 |
| Total Long Term Debt | 1,095.69 | 1,800.86 | 2,387.43 |
| Intangibles Net | 4,481.23 | 3,620.7 | 3,481.46 |
| Other Long Term Assets Total | 1,656.92 | 1,468.33 | 1,366.35 |
| Note Receivable-Long Term | 1,212.46 | 1,208.33 | 816.37 |
| Total Current Assets | 32,708.75 | 27,162.46 | 24,205.63 |
| Capital Lease Obligations | 292.94 | 239.21 | 252.53 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.19
Price to Sale Ratio2.72
Growth
Debt 5Yr CAGR %8.41
Margins
Operating Margin 12m14.86
Operating Margin 5y Avg13.8
Net Profit Margin 12m10.41
Net Profit Margin 5y10.32
Yield
Dividend Yield %0.25
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk27.4
Analyst consensus
ConsensusBuy
Consensus score2.22
Analyst opinions27
Strong Sell count1
Sell count3
Hold count5
Buy count10
Strong Buy count8
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Neuland Laboratories | INR 21,645 | 27,583.36 | 64.28 | — |
| Pfizer | INR 4,900 | 22,334.85 | 27.53 | — |
| Unichem Laboratories | INR 493.05 | 3,476.61 | 54.27 | — |
| Jagsonpal Pharmaceuticals | INR 236.75 | 1,560.88 | 34.27 | — |
| Themis Medicare | INR 112.65 | 1,035.27 | 632.19 | — |
Shareholding
Ownership
- Promoter
- 51.88%
- FII
- 16.38%
- MF
- 16.71%
- Other
- 15.03%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Voltas, Auro Pharma, Federal Bank: Stocks to trade—check price targets, stop loss & more - MSNMarket news · 6 Jun 2026, 8:58 am
Voltas, Auro Pharma, Federal Bank: Stocks to trade—check price targets, stop loss & more MSN
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO - Indian Pharma PostMarket news · 5 Jun 2026, 6:12 pm
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO Indian Pharma Post
USFDA Clears Aurobindo Pharma's Generic Xeljanz Tablets for Arthritis, Ulcerative Colitis - Medical DialoguesMarket news · 5 Jun 2026, 5:57 pm
USFDA Clears Aurobindo Pharma's Generic Xeljanz Tablets for Arthritis, Ulcerative Colitis Medical Dialogues
Aurobindo Pharma - Retail investors' picks: 11 high-margin stocks surge up to 40% in CY26 - The Economic TimesMarket news · 5 Jun 2026, 4:52 pm
Aurobindo Pharma - Retail investors' picks: 11 high-margin stocks surge up to 40% in CY26 The Economic Times
Aurobindo Pharma officials to attend UBS virtual investor meet - scanx.tradeMarket news · 5 Jun 2026, 12:56 pm
Aurobindo Pharma officials to attend UBS virtual investor meet scanx.trade
Aurobindo Pharma gains on getting USFDA`s final nod for Tofacitinib Tablets - Investment Guru IndiaMarket news · 5 Jun 2026, 12:12 pm
Aurobindo Pharma gains on getting USFDA`s final nod for Tofacitinib Tablets Investment Guru India
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- annual General MeetingBuy Back of Shares
- board MeetingsBuy Back of Shares
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Aurobindo Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- AUROPHARMA
- BSE Code
- 524804
Questions
Stock FAQ
What is the symbol and ISIN of Aurobindo Pharma?
Aurobindo Pharma has the symbol AUROPHARMA and ISIN - INE406A01037.
What is the current price of Aurobindo Pharma?
Aurobindo Pharma is currently trading at INR 1,643.00.
What are the year high and year low of Aurobindo Pharma?
Aurobindo Pharma has a year high of INR 1,717.00 and a year low of INR 1,036.00.
What is the market capitalization of Aurobindo Pharma?
Aurobindo Pharma has a market capitalization of INR 91,456.32 crore.
What is the P/E ratio of Aurobindo Pharma?
Aurobindo Pharma has a P/E ratio of 21.62.
What is the dividend yield of Aurobindo Pharma?
Aurobindo Pharma has a dividend yield of 0.25%.
How is the financial performance of Aurobindo Pharma based on revenue, net income, and EPS?
Aurobindo Pharma has revenue of INR 33,653.08 crore, net income of INR 3,504.75 crore, and EPS of INR 61.11.
What is the book value of Aurobindo Pharma?
Aurobindo Pharma has a book value of INR 561.46.
What is the debt-to-equity ratio of Aurobindo Pharma?
Aurobindo Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Aurobindo Pharma?
Aurobindo Pharma has a price-to-book ratio of 2.93 and a price-to-sales ratio of 2.72.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.